Characterization and management of adverse events observed with mobocertinib (TAK-788) treatment for EGFR exon 20 insertion-positive non-small cell lung cancer
Journal
Expert review of anticancer therapy
Journal Volume
23
Journal Issue
1
Date Issued
2023-01
Author(s)
Zhou, Caicun
Jänne, Pasi A
Ramalingam, Suresh S
Kim, Tae Min
Riely, Gregory J
Spira, Alexander I
Piotrowska, Zofia
Mekhail, Tarek
Garcia Campelo, Maria Rosario
Felip, Enriqueta
Bazhenova, Lyudmila
Jin, Shu
Kaur, Manmit
Diderichsen, Paul M
Gupta, Neeraj
Bunn, Veronica
Lin, Jianchang
N Churchill, Eric
Mehta, Minal
Nguyen, Danny
Abstract
Mobocertinib has demonstrated durable clinical benefit in platinum-pretreated patients (PPP) with epidermal growth factor receptor exon 20 insertion-positive non-small cell lung cancer (NSCLC).
Subjects
Carcinoma; drug-related side effects and adverse reactions; epidermal growth factor receptor; non–small cell lung; patient safety; protein tyrosine kinases
SDGs
Publisher
TAYLOR & FRANCIS LTD
Type
journal article